Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen

Journal of Infection in Developing Countries

Volumn 7, Issue 5, 2013, Pages 404-412

  Bin Ghouth, Abdulla Salim ^a,b,c  

^a Hadramout University for Science and Technology   (Yemen)

^b Hadramout Governorate ^*

^c Office of Ministry of Public Health and Population   (Yemen)

Author keywords

Malaria; Private; Surveillance; Yemen

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ARTICLE; CLINICAL TRIAL; EQUIPMENT; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE PRACTICE; HUMAN; MALARIA; MARKETING; ORGANIZATION AND MANAGEMENT; PHARMACIST; PREGNANCY; PRESCRIPTION; QUESTIONNAIRE; YEMEN;

ANTIMALARIALS; FEMALE; GUIDELINE ADHERENCE; HUMANS; INTERVENTION STUDIES; MALARIA; MALE; PREGNANCY; PRESCRIPTIONS; PRIVATE PRACTICE; YEMEN;

EID: 84877908487     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2528     Document Type: Article

References (23)

1. WHO (2010) Guideline for malaria treatment. 2nd edition. 14-21. Available at: http://www.who.int/malaria/publications accessed 30 April 2013.
2. Ministry of Public Health and Population (Yemen) The strategic plan for the national malaria control program 2011-2020. (unpublished report).
3. Manirakiza A, Njuimo SP, Le Faou A, Malvy D, Millet P (2009) Availability of anti-malarial drugs and evaluation of the attitude and practices for the treatment of uncomplicated malaria in Bangui, Central African Republic. East Afr J Public Health 6: 292-295.
4. Oreagba IA, Olayemi SO, Omotosho SK, Onajole AT, Awodele O, Akinyede AA (2008) The use of artemisininbased combination therapies (ACTs) in public secondary health facilities in Lagos, Nigeria. Niger Postgrad Med J 15: 94-100.
5. Gbotosho GO, Happi CT, Ganiyu A, Ogundahunsi OA, Sowunmi A, Oduola AM (2009) Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy. Malar J 30: 313.
6. Abuaku BK, Koram KA, Binka FN (2005) Anti-malarial prescribing practices: a challenge to malaria control in Ghana Med PrincPract 14: 332-337.
7. Iizuka T, Zhe Jin G (2005) The effect of prescription drug advertising on doctor visits. Journal of Economics & Management Strategy 14: 701-727.
8. Ndyomugyenyi R, Magnussen P, Clarke S (2007) Malaria treatment-seeking behavior and drug prescription practices in an area of low transmission in Uganda: implications for prevention and control. Transactions of the Royal Society of Tropical Medicine and Hygiene 101: 209-215.
9. Chiguzo AN, Mugo RW, Wacira DG, Mwenda JM, Njuguna EW (2008) Delivering new malaria drugs through grassroots private sector. East Afr Med J 85: 425-431.
10. Kamat VR (2001) Private practitioners and their role in the resurgence of malaria in Mumbai (Bombay) and Navi Mumbai (New Bombay), India: Serving the affected or aiding an epidemic. SocSci Med 52: 885-909.
11. Bin Ghouth AS and Al-Kaldy KH (2008) Assessment the role and contribution of Private Sector in Case Management of Malaria in Hadramout (Governorate) in Yemen. TDR/EMRO project.
12. Ministry of public health and population -Yemen (2009) The national guideline for anti-malaria drugs.
13. Brugha R, Chandramohan D, Zwi A (1999) Viewpoints: management of malaria working with the private sector. Trop Med Int Health 4: 402-406.
14. Rutta E, Kibassa B, McKinnon B, Liana J, Mbwasi R, Mlaki W, Embrey M, Gabra M, Shekalaghe E, Kimatta S, Sillo H (2001) Increasing access to subsidized artemisinin-based combination therapy through accredited drug dispensing outlets in Tanzania. Health Res Policy Syst 9: 22
15. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, Odhiambo M, Ward L, Goodman C (2009) Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PlosOne 4: e6857
16. Sinclair D, Donegan S, Lalloo DG (2011) Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 16: CD005967.
17. Praygod G, de Frey A, Eisenhut M (2008) Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review. Malar J 7: 210.
18. Hess KM, Goad JA, Arguin PM (2010) Intravenous artesunate for treatment of severe malaria. Ann Pharmacother 44: 1250-1258.
19. Iskander NM, Youssef TF, Ahmed MR, Mohamed AAK (2010) Ishalofantrine ototoxic? Experimental study on guinea pig cochlea model. J LaryngolOtol 124: 1061-1066.
20. Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F (2009) Fetal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J 8: 289.
21. Noor AM, Rage IA, Moonen B, Snow RW (2009) Health service providers in Somalia: their readiness to provide malaria case management. Malar J 13: 100.
22. Rajakaruna RS, Weerasinghe M, Alifrangis M, Amerasinghe PH, Konradsen F (2006) The role of private drug vendors as malaria treatment providers in selected malaria endemic areas of Sri Lanka. J Vector Born Dis 43: 58-65.
23. Cong LD, Yen PT, Nhu TV, Binh LN (1998) Use and quality of anti-malaria drugs in the private sector in Viet Nam. Bull World Health Organization 76 supp l 1: 51-58.